| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $7.7M | +640.7% |
| Cost of Revenue | $1.1M | — |
| R&D Expense | $332.1M | +38.3% |
| SG&A Expense | $191.3M | +91.8% |
| Operating Income | -$516.8M | -52.5% |
| Pre-tax Income | -$465.1M | -55.9% |
| Income Tax | $180K | — |
| Net Income | -$465.3M | -55.9% |
| EPS (Basic) | -$4.95 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $101.5M | -61.6% |
| Short-term Investments | $926.4M | -15.0% |
| Accounts Receivable | $592K | — |
| Inventory | $2.0M | — |
| Current Assets | $1.05B | -23.8% |
| Total Assets | $1.13B | -21.5% |
| Current Liabilities | $85.1M | +42.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$377.9M | -67.2% |
| Capital Expenditures | $5.8M | +49.9% |
| Investing Cash Flow | $173.9M | +130.3% |
| Financing Cash Flow | $40.6M | -96.0% |
| Free Cash Flow | -$383.7M | -67.0% |
| -34.1% |
| EPS (Diluted) | -$4.95 | -34.1% |
| Total Liabilities |
| $134.2M |
| +22.2% |
| Stockholders' Equity | $992.1M | -25.1% |